What Is Vashe Wound Solution and How Does It Work?

Vashe Wound Solution is a commercially prepared form of hypochlorous acid (HOCl), a molecule your own immune cells produce to kill pathogens. It is FDA-cleared as a wound cleanser and irrigation solution, used in hospitals and outpatient clinics to manage infected, chronic, and surgical wounds. The solution works by leveraging the same antimicrobial chemistry your white blood cells use, but delivered in a stable, ready-to-apply liquid at concentrations designed to destroy bacteria while leaving healthy tissue largely unharmed. That balance between killing power and tissue safety is what sets it apart from older antiseptics like povidone-iodine and chlorhexidine, and it is also where the details get interesting.

The Active Ingredient Your Body Already Makes

Hypochlorous acid is not a synthetic pharmaceutical invented in a lab. It is an endogenous antimicrobial, meaning your body manufactures it on its own. When neutrophils, the most abundant white blood cells, engulf a pathogen, they release an enzyme called myeloperoxidase inside the phagosome, the tiny compartment where captured microbes are digested. That enzyme catalyzes the production of HOCl from hydrogen peroxide and chloride ions.

¹ The HOCl then destroys the trapped microbe’s membranes and proteins. Vashe essentially bottles that same molecule at a controlled concentration, typically in an isotonic saline solution buffered to keep the pH in the range where HOCl is most stable and active.

This biological origin matters for more than marketing. Because HOCl is something human tissue already encounters during normal immune responses, it tends to be far better tolerated on open wounds than chemicals the body has no natural relationship with. Researchers have also found that HOCl-modified proteins in the blood can stimulate immune cells and even help them survive in the presence of toxic antigens, suggesting the molecule plays roles beyond simple germ killing.

How It Kills Bacteria

HOCl is an oxidizing agent, but that term undersells what actually happens at the microbial level. The molecule reacts irreversibly with sulfur- and heme-containing enzymes embedded in bacterial cell membranes. These enzymes are critical to the bacterium’s ability to maintain its membrane integrity and perform cellular respiration. Once HOCl locks onto them, the membrane’s respiratory function collapses, and the cell dies.

² This mechanism is fast and broad. Because HOCl targets fundamental structural components shared across many types of bacteria rather than a narrow metabolic pathway, it is effective against a wide range of organisms, and bacteria have a very hard time developing resistance to it in the way they do with conventional antibiotics.

The speed of this kill matters clinically. In one in vitro study, an HOCl-based irrigant achieved a six-log reduction in free-floating (planktonic) bacteria within five minutes.

³ A six-log reduction means killing 99.9999% of the organisms present. That kind of rapid microbicidal action is what surgeons want when irrigating a wound during an operation.

Breaking Through Biofilms

Bacteria floating freely in a wound are relatively easy to kill. The harder problem is biofilm, the slimy, structured communities that bacteria build on wound surfaces. Biofilm acts like armor: it shields the organisms inside from both the immune system and topical treatments. Most chronic wounds harbor biofilm, and its presence is a major reason wounds stall and refuse to heal.

Vashe has shown strong performance against biofilm in laboratory testing. In one comparative study, Vashe and a similar HOCl product effectively sterilized all tested bacterial and fungal biofilms within ten minutes at every dilution tested, with the exception of Candida albicans.

⁴ That fungal activity is worth noting because many wound care solutions struggle with fungi. In another study, Vashe significantly neutralized biofilms formed by methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, two of the most clinically troublesome wound pathogens.

⁵

That said, not every delivery method amplifies these results. When researchers tested Vashe as an instillation fluid inside a negative-pressure wound therapy (NPWT) system, the results were underwhelming. In an in vitro wound model using multispecies biofilm, Vashe with NPWT failed to achieve significant biofilm reductions even after 48 hours of repeated instillation cycles.

⁶ The likely explanation is that the contact time and volume per instillation cycle were not sufficient to overwhelm established multispecies biofilm in that particular setup. This is a useful reminder that how a wound solution is applied can matter as much as what is in the bottle.

Gentle on Human Tissue

The central challenge of wound antisepsis has always been selectivity. Most agents that kill bacteria also damage the very cells trying to rebuild the wound. Povidone-iodine and hydrogen peroxide are notorious for this. The appeal of HOCl is that, at the concentrations used in wound care, it appears to spare human cells to a degree that older antiseptics do not.

In a head-to-head comparison, undiluted Vashe was significantly less cytotoxic to human cells than 1% povidone-iodine, a competing wound cleanser, and 10% povidone-iodine, while still neutralizing bacteria at comparable levels.

⁵ A separate study tested several commercial hypochlorous acid formulations on human keratinocytes and skin fibroblasts. Some formulations showed no cytotoxicity within fifteen minutes of exposure, while others with different chemical profiles caused significant cell damage even at lower concentrations and shorter contact times.

⁷ This variation among products matters: not all HOCl solutions are created equal. The specific pH, concentration, and buffering system affect how the solution behaves on living tissue.

Concentration is the key variable. Research on HOCl aerosol exposure found that human fibroblasts tolerated 300 parts per million for three minutes with no significant changes in cell shape, membrane integrity, or DNA. But at 500 ppm for nine minutes, cells began dying, rounding up, and detaching from surfaces. After four repeated exposures at that higher dose, fibroblast viability dropped to roughly half, with significant DNA damage and apoptosis.

⁸ The practical lesson is that HOCl is tissue-friendly within a therapeutic window, but exceeding that window by raising the concentration or extending the exposure time reverses the advantage.

How It Stacks Up Against Traditional Antiseptics

Chlorhexidine has long been a go-to wound antiseptic, and in laboratory testing it still kills bacteria faster in the first minute of contact than HOCl does. But the picture shifts at longer contact times and in the presence of biofilm. At five minutes, HOCl solutions at 500 and 1,500 mg/L matched or outperformed chlorhexidine and povidone-iodine. At ten minutes, even a lower 300 mg/L concentration reached that same level of effectiveness.

⁹

Where HOCl really pulls ahead is against biofilm. Chlorhexidine lost the most antimicrobial efficacy when biofilm was present, while HOCl maintained more of its killing power.

⁹ For chronic wounds, where biofilm is almost always part of the problem, that resilience is a genuine clinical advantage. Combine it with the lower cytotoxicity profile described earlier, and you get a solution that is both more effective against the hardest-to-treat bacterial communities and less damaging to the tissue trying to heal underneath.

Clinical Results in Chronic Wounds

Lab results mean little if they do not translate to real patients. In a clinical evaluation of Vashe used on chronic wounds, 86% of all treated wounds healed by the end of the study period, and wounds that had not fully closed still shrank by an average of 47%.

¹⁰ Those numbers are encouraging for a patient population in which wounds often persist for months or years.

Two secondary outcomes stood out in that study. First, every patient who had wound odor at the start of treatment, rated at an average of 4.58 on a ten-point scale, had zero odor by the end. Second, 77% of patients reported pain at baseline with an average score of 4.7. By the end of treatment, no patient reported pain.

¹⁰ Wound odor and pain are not trivial side notes. They are among the most distressing aspects of living with a chronic wound, affecting everything from sleep to social isolation. A treatment that eliminates both while also shrinking the wound is doing several jobs at once.

Activity Against Drug-Resistant Organisms

Antibiotic resistance is the backdrop to most wound care conversations today. MRSA in particular is common in wound infections and extremely difficult to manage with oral or intravenous antibiotics alone. Because HOCl kills bacteria through a physical oxidative mechanism rather than by interfering with a specific metabolic process, resistance development is not expected in the way it occurs with antibiotics.

In a burn intensive care unit, implementing a universal decolonization protocol that included hypochlorous acid bathing led to a significant decrease in total MRSA infections.

¹¹ In a study on epidermolysis bullosa wounds, a condition in which the skin is extremely fragile and chronically colonized, Staphylococcus aureus abundance dropped from dominant levels down to roughly 10% of the wound microbiome within four weeks of HOCl treatment and stayed suppressed at four weeks after treatment ended.

¹² That persistence is notable. And the same study found that bacterial diversity on the wounds improved, meaning the treatment was not just knocking back the dominant pathogen but allowing a healthier mix of organisms to recolonize, which is associated with better healing.

Experimental approaches are pushing this further. An electrochemical bandage that generates HOCl directly at the wound surface achieved up to a 7.66-log reduction in MRSA biofilm when HOCl was produced for six hours.

¹³ That level of biofilm reduction against a resistant organism, achieved without any traditional antibiotic, points toward a future where HOCl-based technology plays an even larger role in managing drug-resistant infections.

Storage and Shelf Life

One of the practical drawbacks of hypochlorous acid is that it is inherently unstable compared to something like a bottle of chlorhexidine that sits on a shelf for years. HOCl degrades over time, and how fast it degrades depends almost entirely on how it is stored.

A stability study found that when HOCl solution was kept in a clear plastic container at room temperature and periodically opened, the concentration dropped by 10% within the first month. Under refrigeration in an opaque container, that same 10% drop took six months. Under ideal conditions, sealed in an airtight, opaque, chemically inert container at around 16 to 20°C, the solution held its concentration for about 34 months before losing 10%.

¹⁴

For clinical use, this means you should store Vashe according to the manufacturer’s instructions, keep it out of direct light, and pay attention to expiration dates. Once opened, the solution starts degrading faster. If you are a patient using Vashe at home for wound care, a bottle left sitting on a sunny bathroom counter for weeks is not the same product it was when you opened it. This is not a concern unique to Vashe; it applies to all HOCl wound solutions.

Cost-Effectiveness

Wound care is expensive, and anything that reduces complications translates directly into cost savings. A cost-effectiveness analysis compared HOCl wound cleanser to standard saline irrigation when both were used alongside ultrasonic debridement for complex wounds. The HOCl group experienced a 55% relative reduction in wound-related complications at fourteen days, and the cost to avoid one additional complication was about $91. The number needed to treat was two, meaning for every two patients treated with HOCl instead of saline, one additional complication was avoided, at an incremental cost of roughly $50 per patient.

¹⁵

Those numbers are attractive by health care standards, where interventions routinely cost thousands of dollars per complication avoided. Fewer wound complications also means fewer courses of antibiotics, fewer clinic visits, and shorter overall treatment timelines, all of which compound the savings. For wound care clinics deciding whether the added expense of HOCl over saline is justified, the evidence suggests it pays for itself quickly.

Where the Evidence Gets Thinner

Most of what we know about Vashe comes from in vitro work, small clinical evaluations, and single-center studies rather than large randomized controlled trials. The clinical evaluation showing 86% healing and complete resolution of odor and pain, for instance, was not a blinded, placebo-controlled trial. It provides real-world evidence that is useful but not the highest grade. Larger trials comparing HOCl wound solutions head-to-head with standard care across multiple institutions and wound types would strengthen the case considerably.

The NPWT instillation finding is another area of honest uncertainty. Vashe works well when applied directly to a wound surface with adequate contact time, but when used as a brief instillation fluid cycled through a negative-pressure system, its biofilm-killing power dropped below meaningful thresholds.

⁶ Clinicians using Vashe with NPWT should be aware that the combination may not deliver the antimicrobial punch they expect, at least not with short instillation dwell times.

There is also an important distinction between wound cleansing and wound treatment. Vashe is FDA-cleared as a wound cleanser and irrigant, not as a drug. It is intended to clean the wound bed, reduce bacterial load, and support the healing environment. It is not a standalone treatment for a deep surgical infection that requires systemic antibiotics, surgical drainage, or both. Clinicians use it as one tool in a broader wound management plan, and patients should understand it the same way.

HOCl Beyond Traditional Wound Irrigation

The applications of hypochlorous acid in medicine keep expanding. When used as an irrigation solution with an ultrasonic delivery system in surgical wounds, HOCl reduced bacterial load by four to six log units. By the time wounds closed, bacterial counts in the saline-treated control group had climbed back up to high levels, while the HOCl-treated group maintained bacterial counts that were orders of magnitude lower. Unsuccessful wound closure rates reflected this gap starkly: over 80% of saline-treated patients experienced failed closure, compared to 25% in the HOCl group.

¹⁶

Dermatology, ophthalmology, and dentistry have all adopted HOCl-based products for surface decontamination and post-procedural care. In ophthalmology, HOCl lid wipes are used for blepharitis management. In dermatology, it appears in post-procedure sprays meant to calm irritation and reduce infection risk after laser resurfacing or chemical peels. These uses all lean on the same core property: HOCl kills pathogens without the stinging, tissue damage, or staining associated with iodine-based and alcohol-based antiseptics. As the molecule moves into more clinical niches, the expectation is that stabilization technology will continue improving shelf life, which has historically been the main practical barrier to wider adoption.

1
PubMed Central. The effects of neutrophil-generated hypochlorous acid and other hypohalous acids on host and pathogens
2
PubMed Central. Hypochlorous Acid as a Potential Wound Care Agent Part I. Stabilized Hypochlorous Acid: A Component of the Inorganic Armamentarium of Innate Immunity
3
PubMed. A Novel Irrigant to Eliminate Planktonic Bacteria and Eradicate Biofilm Superstructure With Persistent Effect During Total Hip Arthroplasty
4
PubMed Central. Comparative Antimicrobial Activity of Commercial Wound-Care Solutions on Bacterial and Fungal Biofilms
5
Advances in Skin & Wound Care. Disruption of Biofilms and Neutralization of Bacteria Using Hypochlorous Acid Solution: An In Vivo and In Vitro Evaluation
6
Journal of Antimicrobial Chemotherapy. The efficacy of antimicrobial solutions against multispecies bacterial biofilm with or without negative pressure wound therapy in an in vitro wound model
7
Journal of Antimicrobial Chemotherapy. Safety and efficacy profiles of different commercial sodium hypochlorite/hypochlorous acid solutions (NaClO/HClO): antimicrobial efficacy, cytotoxic impact and physicochemical parameters in vitro
8
PubMed Central. The HOCl dry fog–is it safe for human cells?
9
PubMed. Antimicrobial efficacy of a very stable hypochlorous acid formula compared with other antiseptics used in treating wounds: in-vitro study on micro-organisms with or without biofilm
10
Advances in Skin & Wound Care. Evaluation of Vashe Wound Therapy in the Clinical Management of Patients with Chronic Wounds
11
PubMed. Universal decolonization with hypochlorous solution in a burn intensive care unit in a tertiary care community hospital
12
PubMed Central. An Acid-Oxidising Solution Containing Hypochlorous Acid Reduces Staphylococcus aureus and Improves Bacterial Diversity in Epidermolysis Bullosa Wounds
13
PubMed Central. Evaluation of treatment of methicillin-resistant Staphylococcus aureus biofilms with intermittent electrochemically generated H(2)O(2) or HOCl
14
Scientific and Technical Bulletin оf State Scientific Research Control Institute of Veterinary Medical Products and Fodder Additives аnd Institute of Animal Biology. STABILITY STUDY OF HYPOCHLORITE ACID SOLUTION, OBTAINED BY ELECTROSYNTHESIS METHOD
15
PubMed Central. Cost-Effectiveness of Hypochlorous Acid Preserved Wound Cleanser versus Saline Irrigation in Conjunction with Ultrasonic Debridement for Complex Wounds
16
PubMed Central. Hypochlorous Acid: Clinical Insights and Experience in Dermatology, Surgery, Dentistry, Ophthalmology, Rhinology, and Other Specialties